ReviewJournal of medical case reports2026
Complete radiological and biochemical remission at 26 months in a young adult with primary mediastinal yolk sac tumor: a case report and literature review on multimodal management.
Review in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary mediastinal yolk sac tumor (PMYST) is an extremely rare and highly malignant germ cell tumor that predominantly affects young males and is associated with a poor prognosis. CASE PRESENTATION: We present the case of a 23-year-old non-smoking male diagnosed with stage III (cT4N0M0) PMYST who received comprehensive treatment guided by a multidisciplinary team (MDT). The treatment regimen included 5 cycles of neoadjuvant chemotherapy with BEP (bleomycin, etoposide, and cisplatin), followed by radical surgery, postoperative radiotherapy, and 4 cycles of adjuvant chemotherapy. Post-treatment, the patient's serum tumor markers normalized, with a partial radiological response (PR) and sustained biochemical remission. As of the latest follow-up in August 2025 (26 months after diagnosis), the patient remains in complete radiological and biochemical remission with no signs of recurrence.
conclusionsThis case demonstrates that an intensive MDT-guided multimodal approach incorporating aggressive neoadjuvant chemotherapy, radical surgery, and consolidative sequential radiotherapy and chemotherapy may lead to encouraging outcomes, including the achievement of complete radiological and biochemical remission documented at 26 months. However, this case is more reflective of individualized treatment for a specific patient, and it also highlights the need for intensified surveillance beyond two years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.